Seizert Capital Partners LLC Grows Position in Bristol-Myers Squibb (NYSE:BMY)

Seizert Capital Partners LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 18.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 717,254 shares of the biopharmaceutical company’s stock after purchasing an additional 109,849 shares during the period. Bristol-Myers Squibb accounts for about 1.7% of Seizert Capital Partners LLC’s holdings, making the stock its 25th biggest position. Seizert Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $37,111,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of BMY. Kinsale Capital Group Inc. raised its holdings in Bristol-Myers Squibb by 23.5% during the 3rd quarter. Kinsale Capital Group Inc. now owns 95,597 shares of the biopharmaceutical company’s stock valued at $4,946,000 after acquiring an additional 18,163 shares during the period. Natixis Advisors LLC grew its position in shares of Bristol-Myers Squibb by 34.9% in the third quarter. Natixis Advisors LLC now owns 446,364 shares of the biopharmaceutical company’s stock valued at $23,095,000 after purchasing an additional 115,361 shares in the last quarter. Mizuho Securities USA LLC raised its stake in shares of Bristol-Myers Squibb by 93.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 301,844 shares of the biopharmaceutical company’s stock valued at $15,617,000 after purchasing an additional 145,551 shares during the period. Coastline Trust Co boosted its stake in Bristol-Myers Squibb by 23.6% in the 3rd quarter. Coastline Trust Co now owns 9,592 shares of the biopharmaceutical company’s stock worth $496,000 after purchasing an additional 1,830 shares during the period. Finally, Altrius Capital Management Inc boosted its stake in Bristol-Myers Squibb by 0.6% in the 3rd quarter. Altrius Capital Management Inc now owns 97,662 shares of the biopharmaceutical company’s stock worth $5,053,000 after purchasing an additional 620 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY stock opened at $56.22 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm’s 50-day moving average price is $52.73 and its two-hundred day moving average price is $47.25. The stock has a market capitalization of $114.02 billion, a price-to-earnings ratio of -15.66, a PEG ratio of 15.83 and a beta of 0.44. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the business earned $2.00 EPS. Bristol-Myers Squibb’s revenue was up 8.4% compared to the same quarter last year. As a group, equities analysts predict that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.27%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -66.85%.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,830 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BMY shares. Jefferies Financial Group increased their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a report on Friday. They issued a “peer perform” rating on the stock. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective for the company. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Barclays lifted their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $54.07.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.